Management of obesity as a chronic disease: Nonpharmacologic, pharmacologic, and surgical options

Obesity Research

Volumn 10, Issue SUPPL. 2, 2002, Pages

  Fujioka, Ken ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

Antiobesity drug; Behavioral modification; Diet; Gastric bypass; Physical activity

Indexed keywords

ANOREXIGENIC AGENT; ANTIOBESITY AGENT;

BEHAVIOR THERAPY; CHRONIC DISEASE; DIET; EXERCISE; GASTROPLASTY; HUMAN; OBESITY; REVIEW; STOMACH BYPASS;

ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; BEHAVIOR THERAPY; CHRONIC DISEASE; DIET; EXERCISE; GASTRIC BYPASS; GASTROPLASTY; HUMANS; OBESITY;

EID: 1842521023     PISSN: 10717323     EISSN: None     Source Type: Journal    
DOI: 10.1038/oby.2002.204     Document Type: Review

References (61)

1. Pi-Sunyer FX, Becker DM, Bouchard C, et al. NHLBI Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Obes Res. 1998;6(Suppl 2):51S-209S.
2. Moloney M. Dietary treatments of obesity. Proc Nutr Soc. 2000;59:601-8.
3. Klein S. Medical management of obesity. Surg Clin North Am. 2001;81:1025-38.
4. Wing RR, Jeffery RW. Food provision as a strategy to promote weight loss. Obesity Res. 2001;9(suppl 4):271S-5S.
5. National Task Force on the Prevention and Treatment of Obesity (NTFPTO). Very low-calorie diets. JAMA. 1993;270:967-74.
6. Pekkarinen T, Mustajoki P. Use of very low-calorie diet in preoperative weight loss: efficacy and safety. Obes Res. 1997;5:595-602.
7. Freedman MR, King J, Kennedy E. Popular diets: a scientific review. Obes Res. 2001;9(suppl 1):1S-40S.
8. Powell JJ, Tucker L, Fisher AG, Wilcox K. The effects of different percentages of dietary fat intake, exercise, and calorie restriction on body composition and body weight in obese females. Am J Health Promot. 1994;8:442-8.
9. Astrup A. The role of dietary fat in the prevention and treatment of obesity. Efficacy and safety of low-fat diets. Int J Obes Relat Metab Disord. 2001;25(suppl 1):S46-S50.
10. St. Jeor ST, Howard BV, Prewitt E, et al. Dietary protein and weight reduction. A statement for healthcare professionals from the Nutrition Committee of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association. Circulation. 2001;104:1869-74.
11. Poirier P, Després J-P. Exercise in weight management of obesity. Cardiol Clin. 2001;19:459-70.
12. Wing RR, Hill JO. Successful weight loss maintenance. Annu Rev Nutr. 2001;21:323-41.
13. Perri MG, Nezu AM, McKelvey WF, Shermer RL, Renjilian DA, Viegener BJ. Relapse prevention training and problem-solving therapy in the long-term management of obesity. J Consult Clin Psychol. 2001;69:722-6.
14. Sbrocco T, Nedegaard RC, Stone JM, Lewis EL. Behavioral choice treatment promotes continuing weight loss: preliminary results of a cognitive-behavioral decision-based treatment for obesity. J Consult Clin Psychol. 1999;67:260-6.
15. Rapoport L, Clark M, Wardle J. Evaluation of a modified cognitive-behavioural programme for weight management. Int J Obes Relat Metab Disord. 2000;24:1726-37.
16. Scheen AJ, Lefebvre PJ. Pharmacological treatment of obesity: present status. Int J Obes Relat Metab Disord. 1999;23(suppl 1):47-53.
17. Glazer G. Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety. Arch Intern Med. 2001;161:1814-24.
18. Carek PJ, Dickerson LM. Current concepts in the pharmacological management of obesity. Drugs. 1999;57:883-904.
19. Munro JF, MacCuish AC, Wilson EM, Duncan LJ. Comparison of continuous and intermittent anorectic therapy in obesity. BMJ. 1968;1:352-4.
20. Truant AP, Olon LP, Cobb S. Phentermine resin as an adjunct in medical weight reduction: a controlled, randomized, double-blind prospective study. Curr Ther Res Clin Exp. 1972;14:726-38.
21. Weintraub M, Hasday JD, Mushlin AI, Lockwood DH. A double-blind clinical trial in' weight control. Use of fenfluramine and phentermine alone and in combination. Arch Intern Med. 1984;144:1143-8.
22. Luque CA, Rey JA. Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for treatment of obesity. Ann Pharmacother. 1999;33:968-78.
23. Bach DS, Rissanen AM, Mendel CM, et al. Absence of cardiac valve dysfunction in obese patients treated with sibutramine. Obes Res. 1999;7:363-9.
24. Meridia Prescribing Information. Abbott Laboratories; 2001.
25. Smith IG. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Family Pract. 2001;50:505-12.
26. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med. 1999;106:179-84.
27. James WPT, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet. 2000;356:2119-25.
28. Hansen DL, Astrup A, Toubro S, et al. Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Int J Obes Relat Metab Disord. 2001;25:496-501.
29. Reimherr FW, Cunningham LA, Batey SR, Johnston JA, Ascher JA. A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients. Clin Ther. 1998;20:505-16.
30. Gadde KM, Parker CB, Maner LG, et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res. 2001;9:544-51.
31. Anderson JW, Frank L, Greenway FL, et al. Bupropion SR enhances weight loss: a 48-week double-blind placebo-controlled trial. Obes Res. 2002;10:633-41.
32. Sachs G, Guille C. Weight gain associated with the use of psychotropic medications. J Clin Psychiatry. 1999;60(suppl 21):16-9.
33. Shapira NA, Goldsmith TD, McElroy SL. Treatment of binge-eating disorder with topiramate: a clinical case series. J Clin Psychiatry. 2000;61:368-72.
34. Littrell KH, Petty RG, Hilligoss NM, Peabody CD, Johnson CG. Weight loss with topiramate. Ann Pharmacother. 2001;35:1141-2.
35. Richard D, Ferland J, Lalonde J, et al. Influence of topiramate in the regulation of energy balance. Nutrition. 2000;16:961-75.
36. York DA, Singer L, Thomas S, Bray GA. Effect of topiramate on body weight and body composition of Osborne-Mendel rats fed a high-fat diet: alterations in hormones, neuropeptide, and uncoupling-protein mRNAs. Nutrition. 2000;16:967-75.
37. Bray G, Klein S, Levy B, et al. Topiramate produces dose-related weight loss in obese patients. Presented at The American Diabetes Association Annual Meeting. June 15, 2002. Abstract A1727-P.
38. Appolinario JC, Coutinho W, Fontenelle L. Topiramate for binge-eating disorder. Am J Psychiatry. 2001;158:967-8.
39. Gordon A, Price LH. Mood stabilization and weight loss with topiramate. Am J Psychiatry. 1999;156:968-9.
40. Dursun SM, Devarajan S. Accelerated weight loss after treating refractory depression with fluoxetine plus topiramate: possible mechanisms of action? Can J Psychiatry. 2001;46:287-8.
41. Teter CJ, Early JJ, Gibbs CM. Treatment of affective disorder and obesity with topiramate. Ann Pharmacother. 2000;34:1262-4.
42. Heck AM, Yanorski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Phannacotherapy. 2000;20:270-9.
43. Finer N, James WPT, Kopelman PG, Lean MEJ, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord. 2000;24:306-13.
44. Hauptman J, Lucas C, Boldrin MN, et al. Orlistat in the long-term treatment of obesity in primary care settings. Arch Family Med. 2000;9:160-7.
45. Hill JO, Hauptman J, Anderson JW, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr. 1999;69:1108-16.
46. Astrup A, Breum L, Toubro S, et al. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial. Int J Obes Relat Metab Disord. 1992;16:269-77.
47. Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab. 2000;2:105-12.
48. Fujioka K, Seaton TB, Rowe E. Sibutramine improves glycemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2000;2:175-87.
49. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care. 1998:1288-98.
50. Lucas KH, Kaplan-Machlis B. Orlistat - a novel weight loss therapy. Ann Pharmacother. 2001;35:314-28.
51. Hauner H. Current pharmacological approaches to the treatment of obesity. Int J Obes Relat Metab Disord. 2001;25(suppl 1):S102-S6.
52. Fanghanel G, Cortinas L, Sanchez-Reyes L, Berber A. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity. Int J Obes Relat Metab Disord. 2000;24:144-50.
53. Blanck HM, Khan LK, Serdula MK. Use of nonprescription weight loss products: results from a multistate survey. JAMA. 2001;286:930-5.
54. Boozer CN, Nasser JA, Heymsfield SB, Wang V, Chen G, Solomon JL. An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial. Int J Obes Relat Metab Disord. 2001;25:316-24.
55. Boozer CN, Daly PA, Homel P, et al. Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial. Int J Obes Relat Metab Disord. 2002;26:593-604.
56. Consensus Development Conference Panel. Gastrointestinal surgery for severe obesity. Ann Intern Med. 1991;115:956-61.
57. National Institutes of Health (NIH). The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. NIH Publication Number 00-4084. Rockville, MD: US Dept of Health and Human Services, National Institute of Health; National Heart, Lung, and Blood Institute; North American Association for the Study of Obesity; 2000.
58. Doherty C. Vertical banded gastroplasty. Surg Clin North Am. 2001;81:1097-112.
59. Brolin RE. Gastric bypass. Surg Clin North Am. 2001;81:1077-95.
60. Monteforte MJ, Turkelson CM. Bariatric surgery for the morbid obese. Obes Surg. 2000;10:391-401.
61. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-9.